Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Globe Newswire•13/08/2026•07:15 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.